Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 252, Issue 6, 2014, Pages 909-915

  Heussen, Florian M ^a   Shao, Qing ^a,b   Ouyang, Yanling ^a   Joussen, Antonia M ^a   Müller, Bert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Aflibercept; Age related macular degeneration; Anti VEGF treatment; Ranibizumab; Tachyphylaxis

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LONGEVITY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; DRUG SUBSTITUTION; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; WET MACULAR DEGENERATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84902245557     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-013-2553-7     Document Type: Article

References (20)

1. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG (2009) Aphase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116:1731-1739
2. Brown DM, Kaiser PK, Michels M, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444 (Pubitemid 44511558)
3. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G; SUSTAIN Study Group (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study. Ophthalmology 118:663-671
4. Lally DR, Gerstenblith AT, Regillo CD (2012) Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 23:182-188
5. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379:1728-1738
6. Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, Tuomi L (2012) HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119:1175-1183
7. Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT, Walsh AC, Sadda SR (2008) Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-relatedmacular degeneration. Invest Ophthalmol Vis Sci 49:3115-3120
8. Binder S (2012) Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 96:1-2
9. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups (2012) Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119:2537-2548
10. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW (2012) Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 154:222-226
11. Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Eliott D, Walsh AC, Hwang J, Sadda SR (2012) Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96:14-20
12. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398 (Pubitemid 34920936)
13. Papadopoulos N, Martin J, Run Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171-185
14. Stewart MW, Rosenfeld PJ (2008) Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 92:667-668 (Pubitemid 351684178)
15. Dixon JA, Oliver SC, Olson JL, Mandava N (2009) VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 18:1573-1580
16. Schaal S, Kaplan HG, Tezel TH (2008) Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115:2199-2205
17. Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, Elner VM, Elner SG, Sternberg P Jr (2002) Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 8:119-126 (Pubitemid 36153599)
18. Espinosa-Heidmann DG, Suner IJ, Hernandez P, Monroy D, Csaky KG, Cousins SW (2003) Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3586-3592 (Pubitemid 36909799)
19. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J (2003) Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3578-3585 (Pubitemid 36909798)
20. Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S (2013) Long-termeffects of ranibizumab treatment delay in neovascular agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol 251(2):453-458